drugset / Trial / NCT04863950
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
NaSingle-groupOpen-labelTreatment
Summary
This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.
Timeline
- Start
- 2022-05-25
- Primary completion
- 2026-08
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imipramine | Small molecule | 200 mg | Oral |
| Subject | Lomustine | Small molecule | 110 mg/m2 | Oral |